Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan

Journal of the Indian Medical Association

Volumn 103, Issue 8, 2005, Pages 444-446

  Zargar, Abdul ^a   Basit, Abdul ^b   Mahtab, Hajera ^c  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b BAQAI MEDICAL UNIVERSITY   (Pakistan)

^c BIRDEM Hospital   (Bangladesh)

Author keywords

Diabetes type 2; Fasting; Ramadan; Sulphonylureas

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEART RECEPTOR; LONG ACTING DRUG; METFORMIN; SULFONYLUREA DERIVATIVE;

ARTICLE; BODY WEIGHT; CALORIC INTAKE; CIRCADIAN RHYTHM; CORONARY ARTERY DISEASE; DIET RESTRICTION; DRUG CHOICE; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; KETOACIDOSIS; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; RAMADAN; SIDE EFFECT;

EID: 28944452256     PISSN: 00195847     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. International Meeting on Diabetes and Ramadan Recommendations: Edition of the Hassan II Foundation for Scientific and Medical Research on Ramadan. Casablanca, Morocco, FRSMR, 1995.
2. King H, Aubert RE, Herman WH - Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 9: 1414-31.
3. Salt I, Benard E, Detournay B, et al, on behalf of the EPIDIAR study group - A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries. Results of the Epidemiology of Diabetes and Ramadan (EPIDIAR) study. Diabetes Care 2004; 27: 2306-11.
4. Sari R, Balci MK, Akbas SH, Avci B - The effects of diet, sulfonylurea, and repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004; 30: 169-77.
5. Aadil N, Houti IE, Moussamih S - Drug intake during Ramadan. BMJ 2004; 329: 778-82.
6. Gharbi M, Akrout M, Zouari B - Food intake during and outside Ramadan (in French). East Medterr Health J 2003; 9: 131-40.
7. Yarahmadi SH, Larijani B, Bastanhagh MH, Pajouhi M, Baradar Jalili R, Zahedi F, et al - Metabolic and clinical effects of Ramadan fasting in patients with type II diabetes. J Coll Physicians Surg Pak 2003; 13: 329-32.
8. Aslam M, Healey MA - Compliance and drug therapy in Moslem patients. J Clin Hosp Pharm 1986; 11: 321-5.
9. Aslam M, Assad A - Drug regimens and fasting during Ramadan: a survey in Kuwait. Public Health 1986; 100: 49-53.
10. Guillausseau PJ, Greb W - 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily. Diabetes and Metabolism 2001; 27: 133-7.
11. Lebowitz HE - Oral antidiabetic agents. In: Kahn RC Weir GC, editors. Joslin's Diabetes Mellitus. Waverly International. 13th ed. 2001; 508-29.
12. Dills DG, Schneider J and the Glimepiride/Glyburide Research group - Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996; 28: 426-9.
13. Francillard M, Frey, N, Paraire M, Laveille C, Jochemsen R. Pharmacokinetics of Diamicron® modified release (MR) in 1007 type 2 diabetic patients. J Nutr Health Aging 2001; 5: 14.
14. Langtry HD, Balfour JA - Glimepiride: a review of its use in the management of type 2 diabetes mellitus. Drugs 1998; 55: 563-84.
15. Schernthaner G, Grimaldi A, et al - GUIDE study: double blind comparison of once daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clinical Investigation 2004; 34: 535-42.
16. Gribble FM, Ashcroft FM - Sulfonylurea sensitivity and adenosine triphosphate- sensitive potassium channels from β-cells and extrapancreatic tissues. Metabolism 2000; 49: 3-6.
17. Hosker JP, Rudenski AS, Burnett MA, et al - Similar reduction of first and second phase β-cell responses at three different glucose levels in type 2 diabetes and the effect of gliclazide therapy. Metabolism 1989; 38: 767-72.
18. Intensive blood-glucose control with sulphonylureas or insulin compare with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
19. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81.
20. Meier JJ, Gallwitz B, Schmidt WE, Mügge A, Nauck MA - Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 90: 9-12.
21. Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med 2000; 342: 1040-2.
22. Sondergaard LG, Monster TB, Johnsen SP, et al - The risk of myocardial infarction and case fatality in users of antidiabetics. Diabetologia 2004; 47: 15.
23. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.